<DOC>
	<DOCNO>NCT01877382</DOCNO>
	<brief_summary>This Phase 1 , open-label study DS-3032b ass safety tolerability , identify maximum tolerate dose ( MTD ) /tentative recommend phase 2 dose ( RP2D ) , assess pharmacokinetic ( PK ) / pharmacodynamic ( PD ) property subject advanced solid tumor lymphomas . Approximately 5 US site plan Part 1 ( Dose Escalation ) . Approximately 10 US site plan Part 2 ( Dose Expansion ) .</brief_summary>
	<brief_title>A Phase 1 Multiple Ascending Dose Study DS-3032b , Oral Murine Double Minute 2 ( MDM2 ) Inhibitor , Subjects With Advanced Solid Tumors Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Has histologically cytologically document advanced solid tumor lymphoma relapse refractory standard treatment , standard treatment available . Subjects melanoma ineligible receive decline ipilimumab treatment , refractory intolerant ipilimumab may enroll . Man woman &gt; = 18 year old . Has Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . Has adequate bone marrow function , define : Platelet count &gt; = 100 x 109/L Hemoglobin &gt; = 9.0 g/dL Absolute neutrophil count &gt; = 1.5 x 109/L . Has adequate renal function , define : Creatinine clearance &gt; = 60 mL/min , calculate use modify Cockcroft Gault equation , ( [ { 140 age year } × { actual weight kg } ] divide [ { 72 × serum creatinine mg/dL } multiply 0.85 female ] ) , OR creatinine = &lt; 1.5 x ULN . Has adequate hepatic function , define : AST/ALT level = &lt; 3 x ULN ( liver metastasis present , = &lt; 5 x ULN ) Bilirubin = &lt; 1.5 x ULN . Has adequate blood clot function , define : International normalized ratio ( INR ) activate partial thromboplastin time ( aPTT ) = &lt; 1.5 x ULN . Subject able provide write informed consent , comply protocol visit procedure , able take oral medication , active infection comorbidity would interfere therapy . Subject ( male female ) childbearing/reproductive potential must agree use doublebarrier contraceptive measure avoid intercourse study 90 day last dose study drug . Subject must fully inform illness investigational nature study protocol ( include foreseeable risk possible side effect ) must sign date IRB [ Institutional Review Board ] approve Informed consent Form [ ICF ] ( include Health Insurance Portability Accountability Act authorization , applicable ) performance study specific procedure test . Is willing provide confirm availability preexist diagnostic resect tumor sample , paraffinembedded section . Providing fresh tumor biopsy optional subject Dose Escalation cohort . Is willing undergo tumor genotyping TP53 mutation , insertion , deletion screening . Confirmation TP53 nonmutant status encourage , require prior DS3032b dose . Is willing provide additional archive sample comprehensive genomic and/or proteomic analysis subject partial response/complete response DS3032b treatment . Has tumor contain nonsynonymous mutation , insertion , deletion TP53 gene determine previously screen . Has history primary central nervous system malignancy . Has gastrointestinal condition could affect absorption DS3032b opinion Investigator . Has uncontrolled infection require intravenous antibiotic , antiviral , antifungal , know human immunodeficiency virus infection , active hepatitis B C infection . Has receive allogeneic bone marrow allogeneic stem cell transplant . Has concomitant medical condition would increase risk toxicity , opinion Investigator Sponsor . Has clinically active brain metastasis , define untreated symptomatic , require therapy steroid anticonvulsant control associate symptom . Subjects treat brain metastasis longer symptomatic require treatment steroid may include study recover acute toxic effect radiotherapy . A minimum 4 week must elapse end whole brain radiotherapy study enrollment ( 2 week stereotactic radiotherapy ) . Has unresolved toxicity previous anticancer therapy , define toxicity ( alopecia ) yet resolve NCICTCAE v4 , grade = &lt; 1 baseline . Subjects chronic grade 2 toxicity may eligible per discretion Investigator Sponsor ( eg , grade 2 chemotherapyinduced neuropathy ) . Had autologous transplant within 3 month start study drug treatment . Is receive concomitant treatment strong inhibitor inducer CYP3A4/5 . Had systemic treatment anticancer therapy , antibodybased therapy , retinoid therapy , hormonal therapy within 3 week study drug treatment ; treatment nitrosoureas mitomycin C within 6 week study drug treatment ; treatment smallmolecule target agent within 2 week study drug treatment . Previous concurrent use hormone replacement therapy , use gonadotropin release hormone modulators prostate cancer , use somatostatin analog neuroendocrine tumor permit therapy change within 8 week study drug treatment . Had therapeutic radiation therapy major surgery within 4 week study drug treatment palliative radiation therapy within 2 week study drug treatment . Participated therapeutic clinical study within 3 week study drug treatment , current participation therapeutic investigational procedure . Prolongation correct QT interval Fridericia 's method ( QTcF ) rest , mean QTcF interval &gt; 450 millisecond ( m ) males &gt; 470 m female base triplicate ECG . Pregnant breastfeeding . Substance abuse medical , psychological , social condition , opinion Investigator , may interfere subject 's participation clinical study evaluation clinical study result . Prior treatment MDM2 inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>